- Home
- AIHS vs INDP Comparison
AIHS vs INDP Comparison
Compare AIHS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- INDP
- Stock Information
- Founded
- AIHS 2014
- INDP 2000
- Country
- AIHS China
- INDP United States
- Employees
- AIHS N/A
- INDP N/A
- Industry
- AIHS Finance: Consumer Services
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- AIHS Finance
- INDP Health Care
- Exchange
- AIHS Nasdaq
- INDP Nasdaq
- Market Cap
- AIHS 9.7M
- INDP 10.2M
- IPO Year
- AIHS 2018
- INDP N/A
- Fundamental
- Price
- AIHS $0.88
- INDP $0.93
- Analyst Decision
- AIHS
- INDP Strong Buy
- Analyst Count
- AIHS 0
- INDP 2
- Target Price
- AIHS N/A
- INDP $8.50
- AVG Volume (30 Days)
- AIHS 10.7K
- INDP 25.3K
- Earning Date
- AIHS 02-07-2025
- INDP 11-12-2024
- Dividend Yield
- AIHS N/A
- INDP N/A
- EPS Growth
- AIHS N/A
- INDP N/A
- EPS
- AIHS N/A
- INDP N/A
- Revenue
- AIHS $6,067,071.00
- INDP N/A
- Revenue This Year
- AIHS N/A
- INDP N/A
- Revenue Next Year
- AIHS N/A
- INDP N/A
- P/E Ratio
- AIHS N/A
- INDP N/A
- Revenue Growth
- AIHS 3.33
- INDP N/A
- 52 Week Low
- AIHS $0.38
- INDP $0.84
- 52 Week High
- AIHS $1.45
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- AIHS 52.14
- INDP 34.68
- Support Level
- AIHS $0.87
- INDP $0.94
- Resistance Level
- AIHS $0.92
- INDP $1.06
- Average True Range (ATR)
- AIHS 0.04
- INDP 0.05
- MACD
- AIHS 0.00
- INDP 0.00
- Stochastic Oscillator
- AIHS 67.05
- INDP 0.00
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.